At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 84 enrolled
Drug / intervention
CHF 5074 +6 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Placebo-Controlled, Ascending Single-Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of CHF 5074 in Healthy Young Male Subjects
In Brief
A Phase 1 clinical trial evaluating CHF 5074 and placebo for Alzheimer's Disease. Completed, enrolled 84 participants across 1 site.
Detailed Summary
The purpose of this study is to evaluate the safety and tolerability of single oral doses of CHF 5074 in young healthy male volunteers.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlzheimer's Disease
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedAug 2009
Enrollment StartOct 2009
Primary CompletionMay 2010
TodayJul 2026
First PostedAug 7, 2009
Enrollment StartOct 1, 2009
Primary CompletionMay 1, 2010
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 16.9 years ago
Interventions
CHF 5074drug
1x, oral capsule, single dose
placebodrug
placebo, oral capsule, single dose
CHF 5074drug
2x, oral capsule, single dose
CHF 5074drug
4x, oral capsule, single dose
CHF 5074drug
8x, oral capsule, single dose
CHF 5074drug
16x, oral capsule, single dose
CHF 5074drug
24x, oral capsule, single dose